Diagnostic evaluation of the amastin protein from Leishmania infantum in canine and human visceral leishmaniasis and immunogenicity in human cells derived from patients and healthy controls

Vale, Danniele L.; Dias, Daniel Lucas Santos; Machado, Amanda S.; Ribeiro, Patrícia A.F.; Lage, Daniela P.; Costa, Lourena E.; Steiner, Bethina T.; Tavares, Grasiele S.V.; Ramos, Fernanda F.; Martínez‐Rodrigo, Abel; Chávez-Fumagalli, Miguel Á.; Caligiorne, Rachel Basques; Magalhães-Soares, Danielle F. de; Silveira, Júlia A.G.; Machado-de-Ávila, Ricardo Andrez; Teixeira, Antônio Lúcio; Coelho, Eduardo Antônio Ferraz

doi:10.1016/j.diagmicrobio.2019.04.015

Cited by 13 publications

(12 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar analyses have already been performed in other works, where linear B-cell epitopes were employed for serological detection of several pathogenic organisms, such as Borrelia miyamotoiis (Tokarz et al, 2019), Toxoplasma gondii (Gatkowska et al, 2019), Treponema pallidum (Ogden et al, 2019), Leishmania spp. (Bremer Hinckel et al, 2019;Vale et al, 2019), and several human viruses (Amrun et al, 2019;Mutsvunguma et al, 2019;Yao et al, 2019). This reinforces the importance of these analyses, demonstrating the applications of linear B-cell epitopes in the diagnosis of human pathogenic organisms.…”

Section: Discussionsupporting

confidence: 66%

Immunoproteomic Approach of Extracellular Antigens From Paracoccidioides Species Reveals Exclusive B-Cell Epitopes

et al. 2020

View full text Add to dashboard Cite

Fungi of the Paracoccidioides genus are the etiological agents of paracoccidioidomycosis (PCM), a systemic mycosis restricted to the countries of Latin America. Currently, the Paracoccidioides complex is represented by Paracoccidioides lutzii, Paracoccidioides americana, Paracoccidioides brasiliensis, Paracoccidioides restrepiensis, and Paracoccidioides venezuelensis. Even with advances in techniques used for diagnosing fungal diseases, high rates of false-positive results for PCM are still presented. Additionally, there is no efficient antigen that can be used to follow up the efficiency of patient treatment. The immunoproteomic is considered a powerful tool for the identification of antigens. In addition, antigens are molecules recognized by the immune system, which make them excellent targets for diagnostic testing of diseases caused by microorganisms. In this vein, we investigated which antigens are secreted by species representing Paracoccidioides complex to increase the spectrum of molecules that could be used for future diagnostic tests, patient follow-up, or PCM therapy. To identify the profile of antigens secreted by Paracoccidioides spp., immunoproteomic approaches were used combining immunoprecipitation, followed by antigen identification by nanoUPLC-MS E-based proteomics. Consequently, it was possible to verify differences in the exoantigen profiles present among the studied species. Through a mass spectrometry approach, it was possible to identify 79 exoantigens in Paracoccidioides species. Using bioinformatics tools, two unique exoantigens in P. lutzii species were identified, as well as 44 epitopes exclusive to the Paracoccidioides complex and 12 unique antigenic sequences that can differentiate between Paracoccidioides species. Therefore, these results demonstrate that Paracoccidioides species have a range of B-cell epitopes exclusive to the complex as well as specific to each Paracoccidioides species. In addition, these analyses allowed us the identification of excellent biomarker candidates for epidemiology screening, diagnosis, patient follow-up, as well as new candidates for PCM therapy.

show abstract

Section: Discussionsupporting

confidence: 66%

Immunoproteomic Approach of Extracellular Antigens From Paracoccidioides Species Reveals Exclusive B-Cell Epitopes

et al. 2020

View full text Add to dashboard Cite

show abstract

“…[ 82 ], in which the cases were selected from a health service or hospital. To assess the performance of peptide-based tests, three different formats were reported: one study used an ICT format [ 7 ], two studies used phage-ELISA [ 15 , 62 ] and 19 studies used an ELISA technique [ 10 , 11 , 16 , 17 , 26 , 27 , 29 , 35 , 37 , 40 – 43 , 47 , 48 , 58 , 63 , 69 , 70 ]. In these studies using an ELISA method, a marked difference was observed in the amount of peptides used, which ranged from 0.25 μg to 20 μg per well.…”

Section: Resultsmentioning

confidence: 99%

“…et al ., 2019 [ 63 ] Peptide Parasitology and molecular technique (TL patitents); serology (control group) ELISA 1.5 μg/well II TL Brazil L. braziliensis Vale, D.L. et al ., 2019 [ 69 ] Peptide Molecular technique ELISA 1 μg/well II VL Brazil L. infantum Vale, D.L. et al ., 2022 [ 70 ] PepA Molecular technique ELISA 5 μg/well II TL and VL Brazil L. braziliensis (TL); L. infantum (VL) PepB PepC PepD PepE PepF PepG …”

Section: Resultsmentioning

confidence: 99%

A systematic review of peptide-based serological tests for the diagnosis of leishmaniasis

et al. 2023

View full text Add to dashboard Cite

Serological methods should meet the needs of leishmaniasis diagnosis due to their high sensitivity and specificity, economical and adaptable rapid diagnostic test format, and ease of use. Currently, the performances of serological diagnostic tests, despite improvements with recombinant proteins, vary greatly depending on the clinical form of leishmaniasis and the endemic area. Peptide-based serological tests are promising as they could compensate for antigenic variability and improve performance, independently of Leishmania species and subspecies circulating in the endemic areas. The objective of this systematic review was to inventory all studies published from 2002 to 2022 that evaluate synthetic peptides for serological diagnosis of human leishmaniases and also to highlight the performance (e.g., sensitivity and specificity) of each peptide reported in these studies. All clinical forms of leishmaniasis, visceral and tegumentary, and all Leishmania species responsible for these diseases were considered. Following PRISMA statement recommendations, 1,405 studies were identified but only 22 articles met the selection criteria and were included in this systematic review. These original research articles described 77 different peptides, of which several have promising performance for visceral or tegumentary leishmaniasis diagnosis. This review highlights the importance of and growing interest in synthetic peptides used for serological diagnosis of leishmaniases, and their performances compared to some widely used tests with recombinant proteins.

show abstract

“…Initially, spleens were collected from BALB/c mice that had been vaccinated with ChimeraT/liposome, ChimeraT/saponin, ChimeraT/saline, saline, saponin, or empty liposome but were not infected with L. infantum . Spleen cells were cultured and stimulated with ChimeraT and SLA, in order to examine the specificity of the cytokine response to the vaccinating antigen and to the parasite protein extract, respectively [ 58 , 59 , 60 , 61 , 62 , 63 ]. Spleen cell supernatants were collected, and the production of selected Th1 and Th2-type cytokines was evaluated as markers of the cellular immune response and as an indicator of the potential efficacy of the immunogen against infection by the parasites [ 64 , 65 , 66 ].…”

Section: Resultsmentioning

confidence: 99%

Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Leishmaniases are neglected diseases caused by infection with Leishmania parasites and there are no human vaccines in use routinely. The purpose of this study was to examine the immunogenicity of ChimeraT, a novel synthetic recombinant vaccine against visceral leishmaniasis (VL), incorporated into a human-compatible liposome formulation. Methods: BALB/c mice were immunized subcutaneously with ChimeraT/liposome vaccine, ChimeraT/saponin adjuvant, or ChimeraT/saline and immune responses examined in vitro and in vivo. Results: Immunization with the ChimeraT/liposome formulation induced a polarized Th1-type response and significant protection against L. infantum infection. ChimeraT/liposome vaccine stimulated significantly high levels of interferon (IFN)-γ, interleukin (IL)-12, and granulocyte macrophage-colony stimulating factor (GM-CSF) cytokines by both CD4 and CD8 T-cells, with correspondingly lower levels of IL-4 and IL-10 cytokines. Induced antibodies were predominantly IgG2a isotype, and homologous antigen-stimulated spleen cells produced significant nitrite as a proxy for nitric oxide (NO). Furthermore, we examined a small number of treated VL patients and found higher levels of circulating anti-ChimeraT protein IgG2 antibodies, compared to IgG1 levels. Conclusions: Overall, the liposomal formulation of ChimeraT induced a protective Th1-type immune response and thus could be considered in future studies as a vaccine candidate against human VL.

show abstract

Diagnostic evaluation of the amastin protein from Leishmania infantum in canine and human visceral leishmaniasis and immunogenicity in human cells derived from patients and healthy controls

Cited by 13 publications

References 49 publications

Immunoproteomic Approach of Extracellular Antigens From Paracoccidioides Species Reveals Exclusive B-Cell Epitopes

Immunoproteomic Approach of Extracellular Antigens From Paracoccidioides Species Reveals Exclusive B-Cell Epitopes

A systematic review of peptide-based serological tests for the diagnosis of leishmaniasis

Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis

Contact Info

Product

Resources

About